泛福舒治疗稳定期支气管扩张症的疗效观察

The efficacy of OM-85 in the treatment of stable bronchiectasis

目的研究泛福舒(细菌溶解产物)对稳定期支气管扩张症患者的急性发作相关指标和免疫功能的影响.方法将62例支气管扩张症病人随机分成治疗组34例和对照组28例.对照组给予常规平喘和祛痰的西医治疗,治疗组则在对照组基础上加用泛福舒(7mg/d口服,每月连续10天,停20天,持续3个月)治疗.治疗前后分析两组急性加重次数、持续天数和抗生素使用的时间、以及血清中C3、C4和Ig水平差异.结果治疗后急性发作次数、持续天数和抗生素使用时间,治疗组各指标均优于对照组(P<0.05);对照组在治疗前后血清中的各观察指标水平未见明显改变(P>0.05),治疗组治疗前后补体C3、C4、血清免疫蛋白(IgM、IgG、IgA)明显升高,IgE水平明显下降(P<0.05);与对照组比较(P<0.05).结论泛福舒治疗稳定期支气管扩张症可明显提高患者的免疫功能,增强机体的抗感染能力,减少急性发作次数、急性发作持续天数和抗生素使用的时间,临床疗效较好.

Objective To evaluate the efficacy of OM-85(bacterial lysate) on acute attacks-related indicators and immune function in patients with stable bronchiectasis.Methods 62 patients with bronchiectasis were randomly divided into treatment group(N=34) and control group(N=28). The control group received standard optimized care and the treatment group received treatment with OM-85 oral(dten consecutive days per month, for 3 months). The serum levels of C3, C4, and Ig were observed before and after treatment. The number and duration of acute exacerbations, and time for the use of antibiotics were compared between the two groups after treatment.Results The indexes in the treatment group were lower than those in the control group(P<0.05). There were no significant changes in the various indicators before and after treatment in the control group(P>0.05). In the treatment group, complement C3, C4, serum immune proteins(IgM, IgG and IgA) were significantly increased and IgE levels were significantly decreased before and after treatment(P<0.05). The levels of C3, C4,IgM, IgG and IgA in the treatment group were significantly higher than those in the control group, and the IgE level was lower than that in the control group(P<0.05).Conclusion The application of OM-85 in the stable bronchiectasis can improve the patient’s immune function, enhance the body’s anti-infective ability, reduce the number of acute attacks, the duration of acute attacks and the use of antibiotics.